5 Most Promising Gene Editing Stocks According to Analysts

In this article, we will take a look at the 5 most promising gene editing stocks according to analysts. To see more such companies, go directly to 11 Most Promising Gene Editing Stocks According to Analysts.

5. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 25

One-Year Average Price Target: $12.13

Pacific Biosciences of California, Inc. (NASDAQ:PACB) provides key technologies related to RNA Sequencing, Epigenetics, Target Sequencing, Whole Genome Sequencing and more. In February, Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its fourth quarter results. Adjusted EPS in the period came in at -$0.35, beating estimates by $0.02. Revenue in the period fell about 24% on a YoY basis to reach $0.06 million. Pacific Biosciences of California, Inc. (NASDAQ:PACB) said that it received record orders in the fourth quarter.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is gaining the spotlight after revealing its new long-read sequencer, known as Revio. Revio is the first sequencer to use Nvidia’s (NVDA) GPUs and the throughput of its new SMRT cell is 15 times higher than the Sequel II.

As of the end of the fourth quarter of 2022, 25 hedge funds out of the 943 funds tracked by Insider Monkey reported having stakes in Pacific Biosciences of California, Inc. (NASDAQ:PACB). The net worth of these stakes at the end of the period was about $384 million. Like PACB, Intellia Therapeutics Inc (NASDAQ:NTLA), Crispr Therapeutics AG (NASDAQ:CRSP) and Editas Medicine Inc (NASDAQ:EDIT) are some of the most promising gene editing stocks.